Holen Sie sich die Stockscreener-App
2.44
1.24%
0.03
Handel nachbörslich:
2.56
0.12
+4.92%
Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten
Alto Neuroscience presents new data at Society of Biological Psychiatry meeting - TipRanks
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day - Business Wire
Analysts Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $15.40 - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wellington Management Group LLP Has $326,000 Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Analysts Set Expectations for ANRO Q1 Earnings - Defense World
Alto Neuroscience initiated with a Buy at H.C. Wainwright - Yahoo Finance
Alto Neuroscience (NYSE:ANRO) Now Covered by Analysts at HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Alto Neuroscience (ANRO) with Buy Recommendation - Nasdaq
Charles Schwab Investment Management Inc. Sells 32,137 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Bank of New York Mellon Corp - Defense World
ANRO stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia
What is William Blair’s Forecast for ANRO Q1 Earnings? - Defense World
What is Wedbush’s Estimate for ANRO FY2029 Earnings? - Defense World
Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $16.75 - Defense World
William Blair Reiterates “Outperform” Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience says its funded through 2028 - Green Market Report
ALTO NEUROSCIENCE Earnings Results: $ANRO Reports Quarterly Earnings - Nasdaq
Alto Neuroscience Inc. (ANRO) reports earnings - Quartz
Alto Neuroscience Reports Full-Year 2024 Financial Results And Recent Business Highlights - Marketscreener.com
Alto Neuroscience, Inc. SEC 10-K Report - TradingView
Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Thursday - Defense World
ANRO stock touches 52-week low at $3.23 amid market challenges - MSN
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by Rhumbline Advisers - Defense World
Schizophrenia Drugs Market: Top Competitors, Market Share, - openPR
Alto Neuroscience (NYSE:ANRO) Trading Up 8.8% – Should You Buy? - Defense World
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock - Asianet Newsable
1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March - MSN
1 ‘Strong Buy’ Penny Stock With 270% Upside To Load Up On In March - Barchart
Jefferies Predicts Up to ~500% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Alto Neuroscience advances trial for depression treatment - MSN
ANRO stock touches 52-week low at $2.97 amid market challenges - Investing.com Canada
Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
Can Alto Neuroscience's March Conference Circuit Reveal New Neuropsychiatric Drug Progress? - Stock Titan
Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram Biomarker - Marketscreener.com
Revolutionary Depression Treatment Patent: How Alto's EEG Biomarker Could Transform Patient Care - StockTitan
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker - Business Wire
Promising US Penny Stocks To Watch In February 2025 - simplywall.st
Alto Neuroscience reports positive outcomes from Phase IIb trial of MDD therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Stifel maintains Buy on Alto Neuroscience stock, $10 target - MSN
0.78%
2.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):